The seemingly agreeable path of antibody drug development from discovery to market in the modern world is actually filled with what-ifs, in many cases due to inadequate antibody molecules that are robust and “smart” enough to meet the ever-increasing research and clinical requirements. Single B cell screening is an up-to-date antibody discovery strategy that, unlike hybridoma technology, screens primary B cells to obtain diverse antibody candidates. As introduced in the presentation, Biointron’s single B cell screening platform (AbDrop™) is a microfluidic technology-driven, droplet-based, high throughput single B platform for antibody discovery. Integrated with high throughput NGS sequencing and antibody production capacity, AbDrop™ solution achieves antibody discovery goals in a timeline-expediting and diversity-protecting manner. As case studies presented demonstrate, this solution is especially effective for discovery campaigns like challenging targets, rare antibodies, and unique research requirements.